Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

605 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R, Duvic M, Scarisbrick J, Olsen EA, Rozati S, Eggmann N, Goldinger SM, Hutchinson K, Geskin L, Illidge TM, Giuliano E, Elder J, Kim YH. Dummer R, et al. Among authors: duvic m. Ann Oncol. 2014 Sep;25(9):1807-1812. doi: 10.1093/annonc/mdu231. Epub 2014 Jun 19. Ann Oncol. 2014. PMID: 24948692 Free article. Clinical Trial.
Combined modality therapy for cutaneous T-cell lymphoma.
Duvic M, Lemak NA, Redman JR, Eifel PJ, Tucker SL, Cabanillas FF, Kurzrock R. Duvic M, et al. J Am Acad Dermatol. 1996 Jun;34(6):1022-9. doi: 10.1016/s0190-9622(96)90282-0. J Am Acad Dermatol. 1996. PMID: 8647968
Prognostic factor analysis in mycosis fungoides/Sézary syndrome.
Diamandidou E, Colome M, Fayad L, Duvic M, Kurzrock R. Diamandidou E, et al. Among authors: duvic m. J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24. doi: 10.1016/s0190-9622(99)70079-4. J Am Acad Dermatol. 1999. PMID: 10365922
Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.
Olsen E, Duvic M, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Olsen E, et al. Among authors: duvic m. J Clin Oncol. 2001 Jan 15;19(2):376-88. doi: 10.1200/JCO.2001.19.2.376. J Clin Oncol. 2001. PMID: 11208829 Clinical Trial.
The role for interleukin-12 therapy of cutaneous T cell lymphoma.
Rook AH, Zaki MH, Wysocka M, Wood GS, Duvic M, Showe LC, Foss F, Shapiro M, Kuzel TM, Olsen EA, Vonderheid EC, Laliberte R, Sherman ML. Rook AH, et al. Among authors: duvic m. Ann N Y Acad Sci. 2001 Sep;941:177-84. doi: 10.1111/j.1749-6632.2001.tb03721.x. Ann N Y Acad Sci. 2001. PMID: 11594571 Clinical Trial.
605 results